Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Laura Swart

PhD student
LNPs for targeted siRNA delivery to leukaemic tissue
Phone 088 97 29 430

The fusion protein RUNX1/RUNX1T1 is generated by the chromosomal translocation t(8;21) and found in 15% of all pediatric acute myeloid leukemia (AML). It causes leukaemogenic transformation by blocking differentiation and promoting self-renewal. Direct targeting using RNA interference promises a leukaemia-specific therapeutic approach, but remains associated with poor pharmacokinetic (PK) properties. This PhD-project will aim to explore lipid nanoparticles (LNP) for safe and efficacious delivery of siRNA. First, untargeted LNPs will be designed and tested and second, targeted will be designed and tested.


--
  • Increased Bone Marrow Uptake and Accumulation of Very-Late Antigen-4 Targeted Lipid Nanoparticles

    • mei 2023
    • Laura E, Swart, et al
    • Pharmaceutics
  • Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia

    • apr. 2023
    • Hasan, Issa, et al
    • Leukemia
  • A robust post-insertion method for the preparation of targeted siRNA LNPs

    • mei 2022
    • L. E., Swart, et al
    • International Journal of Pharmaceutics
  • The RUNX1/RUNX1T1 network

    • feb. 2021
    • Laura E, Swart, et al
    • Experimental hematology
View all publications